Latest news and press releases about Humacyte, Inc. (HUMA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs).
Price
| Price | $0.57 |
| Market Cap | $96M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 4.30 |
| EV / EBITDA | -1.10 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -938.20% |
| Return on Invested Capital | -89.17% |
| Return on Assets | -70.05% |
| Gross Margin | -666.81% |
| Operating Margin | -5240.78% |
| Net Margin | -4560.82% |
Related companies: ACHV · ARCT · AVIR · FHTX · IMRX · NAUT · SGMT
Explore sector: Healthcare · Biotechnology
More sections of HUMA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks